Impact of coverage-dependent marginal costs on optimal HPV vaccination strategies

Epidemics

Volumn 11, Issue , 2015, Pages 32-47

  Ryser, Marc D ^a   McGoff, Kevin ^a   Herzog, David P ^a   Sivakoff, David J ^b   Myers, Evan R ^c  

^a DUKE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human papillomavirus vaccination; Male HPV vaccination; Marginal distribution costs; Optimal vaccine distribution; Stochastic agent based models

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; DRUG COST; EMPIRICAL RESEARCH; EPIDEMIC; FEMALE; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH PROGRAM; HERD IMMUNITY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; IMMUNIZATION; MALE; MATHEMATICAL MODEL; OPTIMAL VACCINE DISTRIBUTION; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RESOURCE ALLOCATION; SEXUALLY TRANSMITTED DISEASE; STOCHASTIC MODEL; UTERINE CERVIX CANCER; VACCINATION; WART VIRUS; YOUNG ADULT; COHORT ANALYSIS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE ORGANIZATION; PAPILLOMAVIRUS INFECTIONS; PREVENTIVE HEALTH SERVICE; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ADOLESCENT; COHORT STUDIES; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE RATIONING; HUMAN PAPILLOMAVIRUS 16; HUMANS; IMMUNIZATION PROGRAMS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84924560086     PISSN: 17554365     EISSN: 18780067     Source Type: Journal    
DOI: 10.1016/j.epidem.2015.01.003     Document Type: Article

References (57)

1. Bearman P.S., Moody J., Stovel K. Chains of affection: the structure of adolescent romantic and sexual networks: 1. Am. J. Sociol. 2004, 110(1):44-91.
2. Bishai D., McQuestion M., Chaudhry R., Wigton A. The costs of scaling up vaccination in the worlds poorest countries. Health Aff. 2006, 25(2):348-356.
3. Blödt S., Holmberg C., Müller-Nordhorn J., Rieckmann N. Human papillomavirus awareness, knowledge and vaccine acceptance: a survey among 18-25 year old male and female vocational school students in Berlin, Germany. Eur. J. Public Health 2011, ckr188.
4. Bogaards J.A., Kretzschmar M., Xiridou M., Meijer C.J., Berkhof J., Wallinga J. Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models. PLoS Med. 2011, 8(12):e1001147.
5. Boily M.C., Brisson M., Drolet M., Malagon T. Response J. Nat. Cancer Inst. 2013, 105(10):750-751.
6. Brisson M., van de Velde N., Franco E.L., Drolet M., Boily M.C. Incremental impact of adding boys to current human papillomavirus vaccination programs: role of herd immunity. J. Infect. Dis. 2011, 204(3):372-376.
7. Burchell A.N., Coutlée F., Tellier P.P., Hanley J., Franco E.L. Genital transmission of human papillomavirus in recently formed heterosexual couples. J. Infect. Dis. 2011, 204(11):1723-1729.
8. Carvalho A.M., Goncalves S. Epidemics scenarios in the "romantic network". PLoS ONE 2012, 7(11):e49009.
9. Centers for Disease Control and Prevention HPV Vaccine is Recommended for Boys 2014, (accessed August, 2014). http://www.cdc.gov/features/hpvvaccineboys/.
10. Centers for Disease Control and Prevention HPV Vaccination for Preteens and Teens 2014, (accessed July, 2014). http://www.cdc.gov/vaccines/who/teens/vaccines/hpv.html.
11. Centers for Disease Control and Prevention Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014, United States. MMWR Morb. Mortal Wkly Rep. 2014, 63(29):620-624.
12. Chaturvedi A.K., Katki H.A., Hildesheim A., Rodríguez A.C., Quint W., Schiffman M., et al. Human papillomavirus infection with multiple types: pattern of coinfection and risk of cervical disease. J. Infect. Dis. 2011, 203(7):910-920.
13. Chesson H.W., Ekwueme D.U., Saraiya M., Dunne E.F., Markowitz L.E. The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011, 29(46):8443-8450.
14. Crow J.M. HPV: the global burden. Nature 2012, 488(7413):S2-S3.
15. Darden P.M., Thompson D.M., Roberts J.R., Hale J.J., Pope C., Naifeh M., et al. Reasons for not vaccinating adolescents: National Immunization Survey of Teens, 2008-2010. Pediatrics 2013, 131(4):645-651.
16. Darroch J.E., Landry D.J., Oslak S. Age differences between sexual partners in the United States. Fam. Plann. Perspect. 1999, 160-167.
17. Doherty I.A., Minnis A., Auerswald C.L., Adimora A.A., Padian N.S. Concurrent partnerships among adolescents in a Latino community: the Mission District of San Francisco, California. Sex Transm. Dis. 2007, 34(7):437-443.
18. Drolet M., Brisson M., Maunsell E., Franco E.L., Coutlée F., Ferenczy A., et al. The psychosocial impact of an abnormal cervical smear result. Psycho-Oncology 2012, 21(10):1071-1081.
19. Dunne E.F., Nielson C.M., Stone K.M., Markowitz L.E., Giuliano A.R. Prevalence of HPV infection among men: a systematic review of the literature. J. Infect. Dis. 2006, 194(8):1044-1057.
20. Durrett R. Some features of the spread of epidemics and information on a random graph. Proc. Natl. Acad. Sci. USA 2010, 107(10):4491-4498.
21. Elbasha E.H., Dasbach E.J. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010, 28(42):6858-6867.
22. Elbasha E.H., Dasbach E.J., Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg. Infect. Dis. 2007, 13(1):28.
23. Elbasha E.H. Global stability of equilibria in a two-sex HPV vaccination model. Bull. Math. Biol. 2008, 70(3):894-909.
24. Evander M., Edlund K., Gustafsson Å, Jonsson M., Karlsson R., Rylander E., et al. Human papillomavirus infection is transient in young women: a population-based cohort study. J. Infect. Dis. 1995, 171(4):1026-1030.
25. Giuliano A.R., Palefsky J.M., Goldstone S., Moreira E.D., Penny M.E., Aranda C., et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 2011, 364(5):401-411.
26. Giuliano A.R., Lee J.H., Fulp W., Villa L.L., Lazcano E., Papenfuss M.R., et al. Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet 2011, 377(9769):932-940.
27. Goldman B., Rebolj M., Rygaard C., Preisler S., Ejegod D.M., Lynge E., et al. Patterns of cervical coinfection with multiple human papilloma virus types in a screening population in Denmark. Vaccine 2013, 31:1604-1609.
28. Goodreau S.M. A decade of modelling research yields considerable evidence for the importance of concurrency: a response to Sawers and Stillwaggon. J. Int. AIDS Soc. 2011, 14(1):12.
29. Hernandez B.Y., Wilkens L.R., Zhu X., Thompson P., McDuffie K., Shvetsov Y.B., et al. Transmission of human papillomavirus in heterosexual couples. Emerg. Infect. Dis. 2008, 14(6):888.
30. Jemal A., Simard E.P., Dorell C., Noone A.M., Markowitz L.E., et al. Annual report to the nation on the status of cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. J. Natl. Cancer Inst. 2013, 105(3):175-201.
31. Kaestle C.E., Morisky D.E., Wiley D.J. Sexual intercourse and the age difference between adolescent females and their romantic partners. Perspect. Sex Reprod. Health 2002, 304-309.
32. Kim J.J., Goldie S.J. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. Br. Med. J. 2009, 2009.
33. Kim J., Andres-Beck B., Goldie S. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. Br. J. Cancer 2007, 97(9):1322.
34. Kurtz T.G. Solutions of ordinary differential equations as limits of pure jump Markov processes. J. Appl. Probab. 1970, 7(1):49-58.
35. Liddon N., Hood J., Wynn B.A., Markowitz L.E. Acceptability of human papillomavirus vaccine for males: a review of the literature. J. Adolesc. Health 2010, 46(2):113-123.
36. Malagón T., Joumier V., Boily M.C., Van de Velde N., Drolet M., Brisson M. The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: a model-based analysis. Vaccine 2013, 31(13):1740-1747.
37. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J. Infect. Dis. 2013, 208:385-393.
38. Moody J. The importance of relationship timing for diffusion. Soc. Forces 2002, 81(1):25-56.
39. Moscicki A.B., Ellenberg J.H., Farhat S., Xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J. Infect. Dis. 2004, 190(1):37-45.
40. Palefsky J.M., Giuliano A.R., Goldstone S., Moreira E.D., Aranda C., Jessen H., et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N. Engl. J. Med. 2011, 365(17):1576-1585.
41. Partridge J.M., Hughes J.P., Feng Q., Winer R.L., Weaver B.A., Xi L.F., et al. Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J. Infect. Dis. 2007, 196(8):1128-1136.
42. Patel H., Wagner M., Singhal P., Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect. Dis. 2013, 13(1):39.
43. Rosenberg M.D., Gurvey J.E., Adler N., Dunlop M.B., Ellen J.M. Concurrent sex partners and risk for sexually transmitted diseases among adolescents. Sex Transm. Dis. 1999, 26(4):208-212.
44. Santelli J.S., Lowry R., Brener N.D., Robin L. The association of sexual behaviors with socioeconomic status, family structure, and race/ethnicity among US adolescents. Am. J. Public Health 2000, 90(10):1582.
45. Satterwhite C.L., Torrone E., Meites E., Dunne E.F., Mahajan R., Ocfemia M.C.B., et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm. Dis. 2013, 40(3):187-193.
46. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect. Agent Cancer 2012, 7(1):38.
47. Seto K., Marra F., Raymakers A., Marra C.A. The cost effectiveness of human papillomavirus vaccines. Drugs 2012, 72(5):715-743.
48. Shiels M.S., Pfeiffer R.M., Chaturvedi A.K., Kreimer A.R., Engels E.A. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J. Natl. Cancer Inst. 2012, 104(20):1591-1598.
49. Simard E.P., Ward E.M., Siegel R., Jemal A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA - Cancer J. Clin. 2012, 62(2):118-128.
50. Stanley M. Perspective: vaccinate boys too. Nature 2012, 488(7413):S10.
51. Stokley S., Jeyarajah J., Yankey D., Cano M., Gee J., Roark J., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014, United States. MMWR Morb. Mortal Wkly Rep. 2014, 63(29):620-624.
52. Syrjanen K., Hakama M., Saarikoski S., Väyrynen M., Yliskoski M., Duba Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. J. Sex Transm. Dis. 1990, 17(1):15-19.
53. Taira A.V., Neukermans C.P., Sanders G.D. Evaluating human papillomavirus vaccination programs. Emerg. Infect. Dis. 2004, 10(11):1915.
54. Van de Velde N., Brisson M., Boily M.C. Understanding differences in predictions of HPV vaccine effectiveness: a comparative model-based analysis. Vaccine 2010, 28(33):5473-5484.
55. Walker R., Nickson C., Lew J.B., Smith M., Canfell K. A revision of sexual mixing matrices in models of sexually transmitted infection. Stat. Med. 2012, 31(27):3419-3432.
56. Widdice L., Ma Y., Jonte J., Farhat S., Breland D., Shiboski S., et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J. Infect. Dis. 2013, 207(8):1286-1294.
57. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am. J. Epidemiol. 2003, 157(3):218-226.